ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
Frontiers in Pharmacology · 08.01.2025 · 15
DOI: 10.3389/fphar.2024.1536478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.01.2025. Verfasst von Jiali Hu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related deaths worldwide, accounting for nearly 800,000 fatalities annually. ITGAX (Integrin alpha X) is closely associated with immune cells, such as macrophages and dendritic cells. Its involvement in gastric cancer was identified through an analysis of The Gene Expression Omnibus (GEO) database, which highlighted ITGAX as one of four key gastric cancer-related genes. Our study demonstrates that ITGAX expression is significantly elevated in tumor tissues compared to normal tissues and is positively correlated with clinical prognosis in gastric cancer patients from the GEO database. Moreover, ITGAX enhanced cell proliferation, invasion, and tumorigenic capacity in mouse models. Furthermore, we explored the underlying role of ITGAX using Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction networks (PPI) analysis. Our findings reveal that ITGAX promotes gastric cancer progression by driving epithelial-mesenchymal transition pathway (EMT), suggesting its potential as a biomarker for early diagnosis and prognosis in gastric cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
- School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
- Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Ganjiang Chinese Medicine Innovation Center, Nanchang, China.
- Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Zitieren
APA
Hu, J., Cao, J., Huang, S., & Chen, Y. (2025). ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1536478
Vancouver
Hu J, Cao J, Huang S, Chen Y. ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway. Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1536478
BibTeX
@article{Hu2025,
author = {Hu, Jiali and Cao, Jing and Huang, Shanshan and Chen, Yang},
title = {ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {15},
doi = {10.3389/fphar.2024.1536478}
}
EUVIMED